Quality of life after low-dose rate-brachytherapy for prostate carcinoma

• Verfasst von: Bürgy, Daniel [VerfasserIn]
• Verfasst von: Schneiberg, Vincent Thomas [VerfasserIn]
• Verfasst von: Schäfer, Jörg [VerfasserIn]
• Verfasst von: Welzel, Grit [VerfasserIn]
• Verfasst von: Wenz, Frederik [VerfasserIn]
• Titel: Quality of life after low-dose rate-brachytherapy for prostate carcinoma
• Titelzusatz: long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series
• Verf.angabe: Daniel Buergy, Vincent Schneiberg, Joerg Schaefer, Grit Welzel, Lutz Trojan, Christian Bolenz and Frederik Wenz
• E-Jahr: 2018
• Jahr: 22 January 2018
• Umfang: 9 S.
• Fussnoten: Gesehen am 02.09.2019
• Titel Quelle: Enthalten in: Health and quality of life outcomes
• Ort Quelle: London : BioMed Central, 2003
• Jahr Quelle: 2018
• Band/Heft Quelle: 16(2018) Artikel-Nummer 21, 9 Seiten
• ISSN Quelle: 1477-7525
• DOI: doi:10.1186/s12955-018-0844-8
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1675713421

Abstract

Background: Patient-reported health-related quality of life (HRQOL) differs between treatment options for prostate carcinoma. Long-term HRQOL data in brachytherapy series are scarce. Therefore, we analyzed prostate-specific and general HRQOL in patients treated with brachytherapy for prostate carcinoma after long-term follow-up. Methods: Two hundred ninety-six patients with prostate carcinoma were treated with brachytherapy (01/1998-11/2003). General and prostate-specific HRQOL were measured using EORTC-QLQ-C30 and EORTC-QLQ-PR25, respectively. Patients were asked to complete the questionnaires after a median follow-up of 141 (119-181) months. QLQ-C30 results were compared to the German reference population. QLQ-PR25 results were compared to an earlier follow-up after a median of 51 months (no published QLQ-PR25 reference population for comparison). Additionally, a literature review on HRQOL data in brachytherapy series was performed. Results: One hundred six (35.8%) patients were lost to follow-up, 70 (23.6%) had died. 120 (40.5%) patients were contacted. 80 questionnaires were returned (27% of the original cohort; 91% of alive patients were ≥70 years). Sexual activity declined over time (mean scores: 40.5 vs. 45.5; p = 0.006), hormonal treatment-related symptoms, problems associated with incontinence aids, and burden of obstructive urinary symptoms did not differ significantly compared to the 51-month follow-up. General HRQOL was numerically better in our cohort as compared to the German reference population (> 16% relative difference for both age strata; < 70 and ≥70 years). Conclusions: Our results indicate that symptom-burden after long-term follow-up and associated prostate-specific HRQOL remains relatively stable from 51 to 141 months. General HRQOL in surviving patients was numerically better compared to the reference population.